Miami-based Bascom Palmer Eye Institute is the first facility in Florida to place a new implant to slow the symptoms of macular telangiectasia type 2.
Thomas Albini, MD, led the procedure to place the Encelto microscopic implant. The new technology, which uses gene therapy, is the first FDA-approved treatment designed specifically for MacTel treatment, according to a Feb. 19 news release from the University of Miami Miller School of Medicine.
MacTel affects about one in 10,000 individuals and damages the retina in both eyes.
The FDA has approved the treatment for use at any stage of the disease, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
